MoonLake Faces Expanding Securities Suits in SDNY With Lead‑Plaintiff Deadline Approaching

Overview

• At least two cases are pending in the Southern District of New York, including Bridgewood v. MoonLake Immunotherapeutics, No. 1:25-cv-08500, and Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
• Complaints contend MoonLake misled investors by claiming sonelokimab’s smaller Nanobody format would outperform monoclonal rival BIMZELX despite both targeting IL‑17A and IL‑17F.
• The suits follow MoonLake’s September 28 disclosure that VELA Phase 3 results were disappointing, with VELA‑2 missing its primary endpoint and shares dropping about 90% the next trading day.
• The alleged class period runs from March 10, 2024 through September 29, 2025, with motions for lead‑plaintiff appointment due by December 15, 2025.
• Bleichmar Fonti & Auld, Berger Montague, Hagens Berman, Levi & Korsinsky, and Rosen Law Firm are recruiting investors and potential whistleblowers, and no class has been certified.